GLP1R and metabolic dysfunction-associated steatotic liver disease: The results of this study demonstrated that treatment with the GLP-1 agonistexenatide resulted in a reduction in body weight and improvement in fat accumulationin liver tissues in HF-induced NAFLD animal model.